CD99 as a novel therapeutic target on leukemic progenitor cells in FLT3-ITDmut AML

Leukemia. 2022 Jun;36(6):1685-1688. doi: 10.1038/s41375-022-01566-5. Epub 2022 Apr 14.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • 12E7 Antigen
  • Humans
  • Leukemia, Myeloid, Acute* / drug therapy
  • Mutation
  • Nuclear Proteins / genetics
  • Stem Cells
  • fms-Like Tyrosine Kinase 3 / genetics
  • fms-Like Tyrosine Kinase 3 / therapeutic use

Substances

  • 12E7 Antigen
  • CD99 protein, human
  • Nuclear Proteins
  • FLT3 protein, human
  • fms-Like Tyrosine Kinase 3